RDY:NYSE
Dr Reddy's Laboratories Ltd
12,75 US$
arrow_downward
-0,16%(-0,020) 1D
12,75 US$
0,00% (0,00)
bedtimePo uzavření burzy
Zavřeno: 14. 10., 16:00:05 GMT-4 · USD
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro RDY…
Otevřít
12,70 US$
Max.
12,94 US$
Min.
12,65 US$
Trž. kap.
10,77 mld.
Prům. obj.
3,17 mil.
Objem
3,74 mil.
Dividenda
0,65 %
Čtvrtletní dividenda
0,02 US$
Datum ex dividenda
10. 7. 2026
Ukazatel P/E
30,58
52týd. max.
15,67 US$
52týd. min.
11,36 US$
EPS
0,42 US$
Beta
0,30
Akcie v oběhu
834,64 mil.
Počet zaměstnanců
28 tis.
Otevřít
12,70 US$
Max.
12,94 US$
Min.
12,65 US$
Trž. kap.
10,77 mld.
Prům. obj.
3,17 mil.
Objem
3,74 mil.
Dividenda
0,65 %
Čtvrtletní dividenda
0,02 US$
Datum ex dividenda
10. 7. 2026
Ukazatel P/E
30,58
52týd. max.
15,67 US$
52týd. min.
11,36 US$
EPS
0,42 US$
Beta
0,30
Akcie v oběhu
834,64 mil.
Počet zaměstnanců
28 tis.
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
TipRanks
·
před 6 hodinami
Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant
Stock Titan
·
před 6 hodinami
An FDA pre-approval inspection ends with observations at Dr. Reddy’s (RDY) Visakhapatnam plant.
ad-hoc-news.de
·
před 13 hodinami
Dr Reddy stock trades at INR 1,211.20 before October 23 results
Stock Traders Daily
·
před 1 dnem
Liquidity Mapping Around (RDY) Price Events
Profil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Informace o Dr Reddy's Laboratories Ltd
Generální ředitelErez Israeli
Zaměstnanci27,5 tis.
Založeno1984
ÚstředíHaidarábád, Andhrapradéš, Indie
Odvětví-
Webdrreddys.com